Background and Objectives : Risk-adapted therapy for children with HL is directed toward high survival, minimal toxicity and optimal quality of life, with long term follow up. We assess the impact of prognostic factors associated with local treatment failure of pediatric HL patients with unfavorable criteria treated with combined modality: Alternating ABVD (Doxorubicin, Bleomycin, Vinblastine and Decarbazine) and COEP (Cyclophosphamide, Oncovin, Etoposide and Prednisone) chemotherapy and response-based, involved-field radiation for newly diagnosed unfavorable pediatric HL patients, also will detect toxicities and long-term complications observed in the patients. Methods: This prospective study was carried out from January 2010 to January 2018, with a median follow up of 74 months (range 8 - 103 months). 54 patients were eligible for this study stratified into two groups: intermediate risk ( IR ) and high-risk group (HR). Patients were treated with (4 - 6 cycles) and (6 - 8 cycles) respectively of alternating ABVD/COEP chemotherapy followed by involved-field radiation therapy (IFRT): 15 Gy for patients achieved complete response, and 25.5 Gy for those achieved a partial response. Results: 27 patients were IR and 27 patients were HR. There were 16 treatment failures; 5 patients had progressive disease; and 11 patients had a relapse. 9 patients died from their disease progression. The 5-year overall survival (OS) and event-free survival (EFS) rates (±SE) were 81.8% ± 5.7% and 71.8% ± 6.2% respectively. Multivariate analysis revealed that the only independent factor for inferior OS was radiotherapy. Conclusion: Treatment results of unfavourable HL patients in our study are satisfactory for with IR group but not for HR group who needs intensification of therapy. Radiotherapy is considered as a cornerstone in the treatment of the patients with unfavourable criteria with better assessment of early responders needed by PET-CT to identify patients at risk for relapse.
Metzger, M., Krasin, M.J., Hudson, M.M., et al. (2011) Hodgkin Lymphoma. In: Philip, A., Pizzo, M.D. and Poplack, D.G. Eds., Principles and Practice of Pediatric Oncology, 6th Edition, Lippincott Williams and Wilkins, Philadelphia, 638-662.
Kelly, K.M. (2015) Hodgkin Lymphoma in Children and Adolescents: Improving the Therapeutic Index. Blood, 126, 2452-2458. https://doi.org/10.1182/blood-2015-07-641035
Mc Dowell, H.P., Messahel, B. and Oberlin, O. (2006) Hodgkin’s Disease. In: Imbach, P., Kühne, T. and Arceci, R.J., Eds., Pediatric Oncology, 3rd Edition, Springer, Berlin, 268-286.
Donaldson, S.S., Hudson, M.M., Lamborn, K.R., et al. (2002) VAMP and Low-Dose, Involved-Field Radiation for Children and Adolescents with Favorable, Early-Stage Hodgkin’s Disease: Results of a Prospective Clinical Trial. Journal of Clinical Oncology, 20, 3081-3087. https://doi.org/10.1200/JCO.2002.12.101
Pacquement, H., Landman-Parker, J., Leblanc, T., et al. (2000) Localized Childhood Hodgkin’s Disease: Response-Adapted Chemotherapy with Etoposide, Bleomycin, Vinblastine, and Prednisone before Low-Dose Radiation Therapy—Results of the French Society of Pediatric Oncology Study MDH90. Journal of Clinical Oncology, 18, 1500-1507. https://doi.org/10.1200/JCO.2000.18.7.1500
Hundson, M.M., Krasin, M., Link, M.P., et al. (2004) Risk-Adapted, Combined-Modality Therapy with VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin’s Disease. Journal of Clinical Oncology, 22, 4541-4550. https://doi.org/10.1200/JCO.2004.02.139
Schellong, G., Potter, R., Bramswig, J., et al. (1999) High Cure Rates and Reduced Long-Term Toxicity in Pediatric Hodgkin’s Disease: The German-Austrian Multicenter Trial DAL-HD-90. Journal of Clinical Oncology, 17, 3736-3744. https://doi.org/10.1200/JCO.1999.17.12.3736
Hutchinson, R.J., Fryer, C.J., Davis, P.C., et al. (1998) MOPP or Radiation in Addition to ABVD in the Treatment of Pathologically Staged Advanced Hodgkin’s Disease in Children: Results of the Children’s Cancer Group Phase III Trial. Journal of Clinical Oncology, 16, 897-906. https://doi.org/10.1200/JCO.1998.16.3.897
Kelly, K.M. (2012) Management of Children with High-Risk Hodgkin Lymphoma. British Journal of Haematology, 157, 3-13. https://doi.org/10.1111/j.1365-2141.2011.08975.x
Eberle, F.C., Mani, H. and Jaffe, E.S. (2009) Histopathology of Hodgkin’s Lymphoma. The Cancer Journal, 15, 129-137. https://doi.org/10.1097/PPO.0b013e31819e31cf
Lister, T.A., Crowther, D., Sutcliffe, S.B., et al. (1989) Report of a Committee Convened to Discuss the Evaluation and Staging of Patients with Hodgkin’s Disease: Cotswolds Meeting. Journal of Clinical Oncology, 7, 1630-1636. https://doi.org/10.1200/JCO.1989.7.11.1630
Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247. https://doi.org/10.1016/j.ejca.2008.10.026
Peto, R. and Peto, J. (1972) Asymptotically Efficient Rank Invariant Test Procedures. Journal of the Royal Statistical Society. Series A, 135, 185-198. https://doi.org/10.2307/2344317
Kaplan, E.L. and Meier, P. (1958) Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association, 53, 457-481. https://doi.org/10.1080/01621459.1958.10501452
Savage, I. (1956) Contributions to the Theory of Rank Order Statistics: The Two Sample Case. The Annals of Mathematical Statistics, 27, 590-615. https://doi.org/10.1214/aoms/1177728170
Cox, D.R. (1972) Regression Models and Life-Tables. Journal of the Royal Statistical Society: Series B, 42, 187-220.
Fitzgerald, T.J. and Bishop-Jodoin, M. (2017) Hodgkin Lymphoma: Differences in Treatment between Europe and the United States/North America: Evolving Trends in Protocol Therapy. Clinical Medicine Insights: Oncology, 12, 1-12.
Friedmann, A.M., Hudson, M.M., Weinstein, H.J., et al. (2002) Treatment of Unfavorable Childhood Hodgkins Disease with VEPA and Low-Dose, Involved-Field Radiation. Journal of Clinical Oncology, 20, 3088-3094. https://doi.org/10.1200/JCO.2002.03.051
Ballova, V., Ruffer, J.U., Haverkamp, H., et al. (2005) A Prospectively Randomized Trial Carried out by the German Hodgkin Study Group (GHSG) for Elderly Patients with Advanced Hodgkin’s Disease Comparing BEACOPP Baseline and COPP-ABVD (Study HD9 Elderly). Annals of Oncology, 16, 124-131. https://doi.org/10.1093/annonc/mdi023
Gallamini, A., Hutchings, M., Rigacci, L., et al. (2007) Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced Stage Hodgkin’s Lymphoma: A Report from a Joint Italian-Danish Study. Journal of Clinical Oncology, 25, 3746-3752. https://doi.org/10.1200/JCO.2007.11.6525
Ghazaly, M.H., Ali, A.M., Hamza, H.A. and Mohamed, A.M. (2014) Risk-Adapted Therapy of Pediatric Hodgkin Lymphoma in Upper Egypt.
Schwartz, C.L., Constine, L.S., Villaluna, D., et al. (2009) A Risk-Adapted, Response-Based Approach Using ABVE-PC for Children and Adolescents with Intermediate- and High-Risk Hodgkin Lymphoma: The Results of P9425. Blood, 114, 2051-2059. https://doi.org/10.1182/blood-2008-10-184143
Gao, Y.J., Tang, J.Y., Pan, C., et al. (2013) Risk-Adapted Chemotherapy without Procarbazine in Treatment of Children with Hodgkin Lymphoma. World Journal of Pediatrics, 9, 32-35. https://doi.org/10.1007/s12519-012-0390-0
Friedman, D.L., Chen, L., Wolden, S., et al. (2014) Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report from the Children’s Oncology Group Study AHOD0031. Journal of Clinical Oncology, 32, 3651-3658. https://doi.org/10.1200/JCO.2013.52.5410
Kelly, K.M., Sposto, R., Hutchinson, R., et al. (2011) BEACOPP Chemotherapy Is Highly Effective Regimen in Children and Adolescents with High-Risk Hodgkin Lymphoma: A Report from the Children’s Oncology Group. Blood Journal, 117, 2596-2603. https://doi.org/10.1182/blood-2010-05-285379
Gordon, L.I., Hong, F., Fisher, R.I., et al. (2013) Randomized Phase III Trial of ABVD versus Stanford V with or without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology, 31, 684-691. https://doi.org/10.1200/JCO.2012.43.4803
Ebeid, E.N., Zaghloul, M. and Khairy, M. (2006) Clinical Outcome of Pediatric Hodgkin’s Disease in Upper Egypt. Journal of Clinical Oncology, 24, 9035.
Engert, A., Goergen, H., Markova, J., et al. (2017) Reduced-Intensity Chemotherapy in Patients with Advanced-Stage Hodgkin Lymphoma. Updated Results of the Open-Label, International, Randomized Phase 3 HD15 Trial by the German Hodgkin Study Group. HemaSphere, 1, e5. https://doi.org/10.1097/HS9.0000000000000005
Mauz-Korholz, C., Hasenclever, D., Dorffel, W., et al. (2010) Procarbazine-Free OEPA-COPDAC Chemotherapy in Boysand Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin’s Lymphoma: The GPOH-HD-2002 Study. Journal of Clinical Oncology, 28, 3680-3686. https://doi.org/10.1200/JCO.2009.26.9381
Dorffel, W., Luders, H., Ruhl, U., et al. (2013) Treatment of Children and Adolescents with Hodgkin Lymphoma without Radiotherapy for Patients in Complete Remission after Chemotherapy: Final Results of the Multicenter Trial GPOH-HD95. Journal of Clinical Oncology, 31, 1562-1568. https://doi.org/10.1200/JCO.2012.45.3266
Ali, A., Sayed, H., Farrag, A. and El-Sayed, M. (2010) Risk-Based Combined-Modality Therapy of Pediatric Hodgkin’s Lymphoma: A Retrospective Study. Leukemia Research, 34, 1447-1452. https://doi.org/10.1016/j.leukres.2010.06.012
Wolden, S.L., Chen, L., Kelly, K.M., et al. (2012) Long-Term Results of CCG 5942: A Randomized Comparison of Chemotherapy with or without Radiotherapy for Children with Hodgkin’s Lymphoma—A Report from the Children’s Oncology Group. Journal of Clinical Oncology, 30, 3174-3180. https://doi.org/10.1200/JCO.2011.41.1819